Dr Lal PathLabs to Acquire 70% Stake in SN Genelab for Up to ₹199.5 Crore
Dr Lal PathLabs Limited has approved the acquisition of a 70% stake in SN Genelab Private Limited (SN Gene), a diagnostics company focused on genomics services.
The decision was approved by the company’s Board of Directors at its meeting held on September 24, 2026, according to a stock-exchange filing.
The acquisition will make SN Gene a subsidiary of Dr Lal PathLabs once the transaction is completed.
Dr Lal PathLabs Acquisition Details
Under the proposed transaction, Dr Lal PathLabs will acquire 70% of SN Gene from its existing shareholders.
Key details include:
- Target: SN Genelab Private Limited
- Stake acquired: 70%
- Business: Diagnostics – Genomics
- Consideration: Cash
- Base acquisition cost: Up to ₹168 crore
- Performance-linked earn-out: Up to ₹31.5 crore
- Maximum potential consideration: Up to ₹199.5 crore
- Expected completion: By November 30, 2026
- Related-party transaction: No
The ₹31.5 crore earn-out is performance-linked, meaning the final consideration can depend on specified performance conditions.
SN Gene Revenue Rises to ₹57.96 Crore
SN Genelab has reported growth in turnover over the past three financial years.
| Financial Year | Turnover |
|---|---|
| FY2024 | ₹43.27 crore |
| FY2025 | ₹53.36 crore |
| FY2026 | ₹57.96 crore |
The company’s turnover increased from ₹43.27 crore in FY2024 to ₹57.96 crore in FY2026.
This represents an increase of around 34% over two years, based on the figures disclosed by Dr Lal PathLabs.
Why Is Dr Lal PathLabs Acquiring SN Gene?
Dr Lal PathLabs said the acquisition is aimed at strengthening its expertise in genomics and expanding its portfolio of advanced diagnostic services.
SN Gene operates in the diagnostics-genomics segment.
The acquisition therefore expands Dr Lal PathLabs’ presence in a specialised area of diagnostics rather than being an unrelated diversification.
SN Gene was incorporated on December 16, 2013, in Gujarat and is engaged in providing genomics diagnostic services.
Acquisition to Expand Genomics Portfolio
Genomics is becoming an increasingly important part of advanced diagnostics, with applications across areas such as genetic testing and disease-related diagnostic services.
For Dr Lal PathLabs, acquiring a controlling stake in an existing genomics business provides a route to expand its capabilities in this segment.
The company will acquire 70% ownership, while the remaining stake will continue to be held by existing shareholders unless separately disclosed.
No Regulatory Approval Required
According to the company’s disclosure, no governmental or regulatory approvals are required for the proposed acquisition.
The transaction is expected to be completed by November 30, 2026.
Dr Lal PathLabs has also stated that the proposed transaction does not fall within the ambit of related-party transactions.
What Investors Should Watch
For investors tracking Dr Lal PathLabs, the important aspects of the transaction will be the financial performance of SN Gene after consolidation and the company’s ability to scale its genomics business.
Key points to monitor include:
- Completion of the 70% acquisition
- Revenue contribution from SN Gene
- Growth in genomics diagnostic services
- Profitability and margins of the acquired business
- Performance-linked earn-out payments
- Integration with Dr Lal PathLabs’ existing diagnostic network
- Further investments in advanced diagnostics
The acquisition cost of up to ₹168 crore plus a potential ₹31.5 crore performance-linked earn-out should also be considered in assessing the economics of the transaction.
Bottom Line
Dr Lal PathLabs has approved the acquisition of a 70% stake in SN Genelab Private Limited, a genomics-focused diagnostics company.
The company will pay up to ₹168 crore for the 70% stake, along with a performance-linked earn-out capped at ₹31.5 crore, taking the potential total consideration to ₹199.5 crore.
SN Gene’s turnover increased from ₹43.27 crore in FY2024 to ₹57.96 crore in FY2026, according to the disclosure.
The transaction is expected to be completed by November 30, 2026, after which SN Gene will become a subsidiary of Dr Lal PathLabs.
This article is based on Dr Lal PathLabs’ stock-exchange disclosure dated September 24, 2026. It is for informational purposes only and should not be considered investment advice.
